LEXINGTON, Mass.,
June 13, 2017 /PRNewswire/
-- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a
clinical-stage biotechnology company devoted to treating
inflammation, inborn errors of metabolism, and other diseases
related to aldehyde toxicity, announced they will host a conference
call and webcast on Wednesday, June 14,
2017 at 8:00 A.M. EDT to
discuss results from its Phase 2b Allergic Conjunctivitis
Trial.
The dial-in numbers are 1-877-870-4263 for domestic
callers and 1-412-317-0790 for international callers. A live
webcast of the conference call will also be available on the
investor relations page of the Aldeyra Therapeutics corporate
website
at www.aldeyra.com.
After the live webcast, the event will remain archived on
the Aldeyra Therapeutics website for one year.
About Aldeyra
Therapeutics
Aldeyra
Therapeutics, Inc. is a biotechnology company devoted to improving
lives by inventing, developing and commercializing products that
treat diseases thought to be related to endogenous aldehydes, a
naturally occurring class of pro-inflammatory and toxic molecules.
Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in
development for ocular inflammation, as well as for Sjögren-Larsson
Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two
inborn errors of aldehyde metabolism. Aldeyra's product candidates
have not been approved for sale in the U.S. or
elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra
Therapeutics, Inc.
Tel: +1 781-761-4904 ext.
205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke
Partners
Tel:
339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical
Communications
781-591-3443
cduong@macbiocom.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-results-from-allergic-conjunctivitis-phase-2b-clinical-trial-300473316.html
SOURCE Aldeyra Therapeutics, Inc.